Skip to main content
MBOT
NASDAQ Industrial Applications And Services

Microbot Medical's LIBERTY Robotic System Gains Traction at Key Endovascular Conference

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.981
Mkt Cap
$134.316M
52W Low
$1.25
52W High
$4.67
52W Position info
58% above low
Off High info
58% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

MBOT sits 58% above its 52-week low of $1.25.

Summary

Microbot Medical announced its LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy, highlighting its commercial traction and upcoming full market release.


Key Events · Product Development and Regulatory · MBOT

  • LIBERTY System Featured at ISET Conference

    Microbot Medical's LIBERTY Endovascular Robotic System was highlighted at the International Symposium on Endovascular Therapy (ISET) conference, a leading event for endovascular experts.

  • Commercial Traction and Market Adoption

    The system was discussed in a Town Hall session, emphasizing its seamless workflow integration and unique features, which the company believes are key drivers for broader adoption.

  • CEO Highlights Growing Interest

    CEO Harel Gadot noted increasing interest from physicians across multiple specialties and hospitals, reinforcing LIBERTY's broad clinical relevance and expanding commercial opportunity.

  • Full Market Release Planned

    Following a limited market release in late 2025, Microbot Medical plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026.


Analysis · MBOT · Industrial Applications And Services

This 8-K filing provides a positive update on the commercialization efforts for Microbot Medical's LIBERTY Endovascular Robotic System. Its prominent feature at a leading vascular disease management conference, coupled with the CEO's comments on increasing physician interest and broad clinical relevance, suggests growing market acceptance. The planned full market release in April 2026 at the SIR conference indicates a clear strategy for expanding adoption, building on the limited market release initiated in late 2025. This news reinforces the company's progress in transforming endovascular procedures with its FDA-cleared, single-use robotic technology.

At the time of this filing, MBOT was trading at $1.98 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $134.3M. The 52-week trading range was $1.25 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MBOT - Latest Insights

MBOT
Jul 07, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.94
Real-time Price: $1.69 info
Change: -$0.250 (-13%) info
Market Cap: $112.837M info
MBOT
Jul 07, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.03
Real-time Price: $1.69 info
Change: -$0.3419 (-17%) info
Market Cap: $112.837M info
MBOT
Jun 30, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.95
Real-time Price: $1.69 info
Change: -$0.2622 (-13%) info
Market Cap: $112.837M info
MBOT
Jun 30, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.88
Real-time Price: $1.69 info
Change: -$0.190 (-10%) info
Market Cap: $112.837M info
MBOT
Jun 25, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.81
Real-time Price: $1.69 info
Change: -$0.1187 (-7%) info
Market Cap: $112.837M info